Seagull Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.25 M
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 10.30 Cr
- Revenue Growth %
- Profit Growth -65.15%
- Ebitda -68.83%
- Net Worth -24.43%
- Total Assets -17.36%
About Seagull Drugs
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299DL1990PTC039516
- Company No.
039516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 1990
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Seagull Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neelam Oberoi  | Director | 21-Jun-1996 | Current |
| Amir Sehgal | Director | 16-Sep-1996 | Current |
Financial Performance of Seagull Drugs.
Seagull Drugs Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 65.15% decrease in profit. The company's net worth observed a substantial decline by a decrease of 24.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seagull Drugs?
In 2020, Seagull Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ozone Pharmaceuticals LimitedNeelam Oberoi is a mutual person
Charges (Loans)
₹0
₹103.00 M
Charges Breakdown by Lending Institutions
- Citibank N.A : 10.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Mar 2013 | Citibank N.A | ₹10.30 Cr | Satisfied |
How Many Employees Work at Seagull Drugs?
Unlock and access historical data on people associated with Seagull Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seagull Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seagull Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.